Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.71 |
| ▸ | DRD3 | P35462 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.64 |
| ▸ | HTR3B | O95264 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401668 | 0.93 | DRD2 (0.63) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL327835 | 0.83 | DRD2 (1.00) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL3165674 | 0.82 | DRD2 (0.72) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL30407688 | 0.82 | DRD2 (0.72) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL2822342 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL1484038 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL11150752 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL1374764 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL8576226 | 0.81 | DRD2 (0.96) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL3174809 | 0.81 | DRD2 (0.70) | DRD2DRD3CYP2C19HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241554-A1 | QUINOLINE-8-SULFONAMIDE DERIVATES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-2448582-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-1997014419-A1 | TRANSDERMAL DELIVERY OF ALPHA ADRENOCEPTOR BLOCKING AGENTS | FLORA INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | DRD2 1/4885DRD3 12/4885CYP2C19 3841/4885 |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | DRD2 4808/4885DRD3 4849/4885CYP2C19 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.